Novartis scandal

Novartis scandal

TOKYO, Japan - David Epstein (C), division head at Novartis AG, the Swiss-based pharmaceutical giant, and Yoshiyasu Ninomiya (R), president of Novartis Pharma K.K., a Japanese unit of Novartis AG, bow in apology during a press conference in Tokyo on Oct. 3, 2013. Novartis Pharma K.K. has allegedly engaged in deceptive advertizing for the blood pressure-lowering drug Diovan by citing a study based on manipulated clinical data.

Novartis scandal

Novartis scandal

TOKYO, Japan - David Epstein (L), division head at Novartis AG, the Swiss-based pharmaceutical giant, speaks in a press conference in Tokyo on Oct. 3, 2013. At right is Yoshiyasu Ninomiya, president of Novartis Pharma K.K., a Japanese unit of Novartis AG. Novartis Pharma K.K. has allegedly engaged in deceptive advertizing for the blood pressure-lowering drug Diovan by citing a study based on manipulated clinical data.

Novartis division head Epstein

Novartis division head Epstein

TOKYO, Japan - David Epstein (L), division head at Novartis AG, the Swiss-based pharmaceutical giant, holds talks with Japanese Health, Labor and Welfare Minister Norihisa Tamura (R) at the ministry in Tokyo on Sept. 26, 2013. Tamura summoned Epstein and sharply criticized the firm for triggering a scandal involving Novartis Pharma K.K., the Japanese subsidiary of Novartis AG. The unit allegedly engaged in deceptive advertizing for the blood pressure-lowering drug Diovan by citing a study based on manipulated clinical data.

Novartis division head Epstein

Novartis division head Epstein

TOKYO, Japan - David Epstein, division head at Novartis AG, the Swiss-based pharmaceutical giant, speaks with reporters after holding talks with Japanese Health, Labor and Welfare Minister Norihisa Tamura at the ministry in Tokyo on Sept. 26, 2013. Tamura summoned Epstein and sharply criticized the firm for triggering a scandal involving Novartis Pharma K.K., the Japanese subsidiary of Novartis AG. The unit allegedly engaged in deceptive advertizing for the blood pressure-lowering drug Diovan by citing a study based on manipulated clinical data.

Thailand approves plan to treat COVID-19 as endemic

STORY: Thailand approves plan to treat COVID-19 as endemic DATELINE: March 10, 2022 LENGTH: 00:02:48 LOCATION: Bangkok CATEGORY: HEALTH SHOTLIST: 1. various of Thai people's lives, markets 2. various of advertizing board of "We Win" and "We Love Each Other" campaigns 3. various of Thai shopping markets, street view 4. various of people waiting for COVID-19 test 5. various of Thai people receiving COVID-19 vaccine injections STORYLINE: Thailand's health authorities approved on Wednesday a four-step plan to support the country's transition to the COVID-19 endemic phase by July 1. Approved at a meeting held by the National Communicable Disease Committee (NCDC), the plan aims to gradually contain the surge of new infections and deaths caused by the latest Omicron variant, and prepare the country to treat the virus as an endemic. The decision was made to help Thailand's economy recover from the pandemic as well as protect public health by implementing strict measures accordingly, Public Health Minister